BTK and leukemia: Immunoblot analyses showed that targeting Bcl-2 and/or Mcl-1 concomitantly with CG-806 profoundly suppressed Mcl-1, reduced p-FLT3, -BTK, and -AURK, and triggered a marked cleavage of caspase-3 (Fig. 6C), suggesting that the combination regimens trigger potent leukemia cell killing which may translate in beneficial effect in relapsed/refractory AML regardless of FLT3 mutational status.